Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) have earned an average rating of “Moderate Buy” from the fourteen research firms that are currently covering the stock, MarketBeat.com reports. Four equities research analysts have rated the stock with a hold recommendation and ten have issued a buy recommendation on the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $75.00.

Several research firms have recently issued reports on KROS. Wells Fargo & Company increased their price target on Keros Therapeutics from $88.00 to $111.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 11th. Oppenheimer decreased their target price on shares of Keros Therapeutics from $102.00 to $63.00 and set an “outperform” rating for the company in a research report on Monday, December 16th. TD Cowen downgraded shares of Keros Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Truist Financial decreased their price objective on shares of Keros Therapeutics from $100.00 to $43.00 and set a “buy” rating for the company in a report on Monday, December 23rd. Finally, Scotiabank dropped their target price on Keros Therapeutics from $77.00 to $44.00 and set a “sector outperform” rating on the stock in a report on Friday, December 13th.

Keros Therapeutics Stock Down 2.2 %

Keros Therapeutics stock opened at $14.56 on Friday. Keros Therapeutics has a 52-week low of $13.96 and a 52-week high of $73.00. The firm has a market capitalization of $589.78 million, a price-to-earnings ratio of -2.79 and a beta of 1.43. The firm has a 50-day moving average price of $41.71 and a two-hundred day moving average price of $48.32.

Keros Therapeutics (NASDAQ:KROS) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.28) by ($0.13). Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The business had revenue of $0.39 million for the quarter. During the same period in the previous year, the company posted ($1.33) EPS. The company’s revenue for the quarter was up 4750.0% on a year-over-year basis. Research analysts expect that Keros Therapeutics will post -5.26 earnings per share for the current year.

Institutional Investors Weigh In On Keros Therapeutics

Large investors have recently modified their holdings of the stock. Geode Capital Management LLC lifted its holdings in shares of Keros Therapeutics by 6.8% during the third quarter. Geode Capital Management LLC now owns 725,621 shares of the company’s stock valued at $42,146,000 after purchasing an additional 46,041 shares during the last quarter. Barclays PLC lifted its stake in Keros Therapeutics by 140.1% during the third quarter. Barclays PLC now owns 60,014 shares of the company’s stock valued at $3,484,000 after buying an additional 35,022 shares in the last quarter. Wellington Management Group LLP acquired a new position in shares of Keros Therapeutics in the third quarter worth about $868,000. Point72 DIFC Ltd grew its position in Keros Therapeutics by 9.8% during the 3rd quarter. Point72 DIFC Ltd now owns 19,255 shares of the company’s stock worth $1,118,000 after purchasing an additional 1,715 shares in the last quarter. Finally, Point72 Asset Management L.P. grew its holdings in shares of Keros Therapeutics by 155.9% during the third quarter. Point72 Asset Management L.P. now owns 947,570 shares of the company’s stock valued at $55,025,000 after buying an additional 577,220 shares in the last quarter. 71.56% of the stock is owned by institutional investors.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.